Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer

被引：0
|
作者：
Jeffrey Franks
Nicole E. Caston
Ahmed Elkhanany
Travis Gerke
Andres Azuero
Gabrielle B. Rocque
机构：
[1] University of Alabama at Birmingham,Department of Medicine, Division of Hematology and Oncology
[2] O’Neal Comprehensive Cancer Center,School of Nursing
[3] The Prostate Cancer Clinical Trials Consortium,undefined
[4] University of Alabama at Birmingham,undefined
来源：
Breast Cancer Research and Treatment | 2023年 / 197卷
关键词：
Cyclin-dependent kinase 4/6 inhibitors; Visualization; Duration;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：673 / 681
页数：8
相关论文
共 50 条
  • [21] Post-treatment vascularity and vessel shape are associated with survival and response to CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer (MBC)
    Viswanathan, Vidya Sankar
    Braman, Nathaniel
    Reddy, Priyanka
    Kunte, Siddharth
    Abraham, Jame
    Montero, Alberto J.
    Madabhushi, Anant
    CANCER RESEARCH, 2022, 82 (04)
  • [22] Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
    Scheidemann, Erin R.
    Shajahan-Haq, Ayesha N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [23] Targeting CDK6 in hormone receptor-positive breast cancer: inhibitor discovery for precision oncology through dynamics study
    Khatoon, Zeenat
    Khalid, Mohammad
    Alqarni, Mohammed H.
    Foudah, Ahmed I.
    Annadurai, Sivakumar
    Wahab, Shadma
    Almoyad, Mohammad Ali Abdullah
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2025, 43 (06): : 2733 - 2745
  • [24] The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer
    Bao, Kelvin K. H.
    Wong, Carol H. Y.
    Yung, Jackie
    Tam, Venus
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    Yiu, Harry H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] Adjuvant CDK4/6 inhibitors in hormone receptor-positive early breast cancer: one fits all?
    Gianni, Caterina
    Nicolo, Eleonora
    Cristofanilli, Massimo
    TRANSLATIONAL BREAST CANCER RESEARCH, 2024, 5
  • [26] Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
    West, Malinda T.
    Goodyear, Shaun M.
    Hobbs, Evthokia A.
    Kaempf, Andy
    Kartika, Thomas
    Ribkoff, Jessica
    Chun, Brie
    Mitri, Zahi, I
    ONCOLOGIST, 2023, : 682 - 690
  • [27] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Grinshpun, Albert
    Tolaney, Sara M. M.
    Burstein, Harold J. J.
    Jeselsohn, Rinath
    Mayer, Erica L. L.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [28] Everolimus Plus Exemestane Treatment in Patients with Metastatic Hormone Receptor-Positive Breast Cancer Previously Treated with CDK4/6 Inhibitor Therapy
    Cook, Madeline M.
    Al Rabadi, Luai
    Kaempf, Andy J.
    Saraceni, Megan M.
    Savin, Michael A.
    Mitri, Zahi I.
    ONCOLOGIST, 2021, 26 (02): : 101 - 106
  • [29] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Albert Grinshpun
    Sara M. Tolaney
    Harold J. Burstein
    Rinath Jeselsohn
    Erica L. Mayer
    npj Breast Cancer, 9
  • [30] Post-CDK 4/6 Inhibitor Therapy: Current Agents and Novel Targets
    Ashai, Nadia
    Swain, Sandra M.
    CANCERS, 2023, 15 (06)
12345